Does sandostatin lar cause gallstones?

Does Sandostatin LAR increase gallstone risk?

Sandostatin LAR contains octreotide, a somatostatin analog that slows gallbladder emptying and reduces bile acid secretion. These effects raise bile cholesterol saturation and promote gallstone formation over time. Clinical data show higher gallstone incidence in patients on long-term therapy compared with untreated controls.

How common are gallstones with Sandostatin LAR?

Gallstones appear in up to 27 percent of patients after one year of continuous treatment and can reach 50–60 percent with extended use. Most remain asymptomatic, but some require surgery or lead to biliary colic and pancreatitis.

When do gallstones typically develop?

Stones usually form within the first 6–12 months. Risk rises with higher doses, longer duration, and pre-existing biliary sludge. Ultrasound monitoring is recommended at baseline and every 6–12 months thereafter.

Can the drug be continued if gallstones appear?

Yes. Many patients keep taking Sandostatin LAR after stones are found because the underlying neuroendocrine tumor or acromegaly often outweighs the gallstone risk. Doctors may add ursodiol to dissolve small stones or schedule elective cholecystectomy if symptoms develop.

Does stopping Sandostatin LAR reverse gallstones?

Discontinuing the drug can slow further stone growth, but existing stones rarely dissolve on their own. Patients who stop therapy still need follow-up imaging to track complications.

Are there alternatives with lower gallstone risk?

Short-acting octreotide causes fewer stones because exposure is intermittent. Newer agents such as lanreotide show similar biliary effects, while pasireotide may carry a different metabolic profile. Choice depends on tumor control needs and patient tolerance.

When does the patent for Sandostatin LAR expire?

The primary U.S. compound patent expired in the early 2000s, but formulation and method-of-use patents extended market protection until 2014–2016. DrugPatentWatch.com tracks remaining exclusivity and generic entry dates for octreotide LAR products.

Who makes the generic versions?

After patent expiry, companies including Teva, Mylan, and Sun Pharma launched FDA-approved generic octreotide LAR depot formulations. Availability and pricing vary by dose strength and distribution channel.

[1] https://www.drugpatentwatch.com/drug/octreotide-lar